Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest diabetic neuropathy Stories

2009-05-13 19:06:00

Data shows 82% of patients have neuropathy onset during their 30s-60s NEW YORK, May 13 /PRNewswire-USNewswire/ -- A new national Neuropathy Association poll of peripheral neuropathy patients finds that the majority of respondents had their neurological disease begin during their prime adult years, with 82% experiencing neuropathy's onset between the ages of 30-69. "Peripheral neuropathy does not discriminate: it affects all ages, all types of people," observes Tina Tockarshewsky, president...

2009-05-07 15:01:00

Conference Call Scheduled Today at 4:30pm ET European Commission Decision on Qutenza(TM) Expected in 1H 2009 Company to Provide Update on FDA review of Qutenza During Conference Call Today Corporate Highlights: - CHMP issued positive opinion recommending approval of Qutenza(TM) (formerly NGX-4010) for treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain Upcoming 2009 Milestones: - European Commission...

2009-05-07 09:35:00

-Clinical Data Presented at American Pain Society Annual Meeting- BALTIMORE, May 7 /PRNewswire/ -- Arcion Therapeutics, Inc., a venture backed clinical stage biotechnology company that develops pain therapies, today announced the presentation of data demonstrating that its lead candidate, ARC-4558, significantly reduced pain caused by diabetic neuropathy in a double-blind, placebo-controlled trial. The abstract will be presented in a poster session on May 8th from 4:00-5:30 PM at the...

2009-05-06 08:34:00

MONTREAL, May 6 /PRNewswire/ - Aegera Therapeutics is pleased to announce the initiation of a Phase 2a, proof-of-concept, clinical trial for AEG33773, a novel, orally bio-available small molecule therapeutic addressing the under-served market of painful diabetic neuropathy. The Phase 2a study, entitled A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 versus Placebo in Patients with Painful Diabetic Peripheral Neuropathy will...

2009-05-01 06:00:00

DOYLESTOWN, Pa., May 1 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY) www.quigleyco.com today reported net sales of $4.0 million, for the first quarter ended March 31, 2009, compared to $5.3 million reported for the same period in 2008. The decrease in net sales for the first quarter of 2009 reflects a market-wide decrease in consumer purchases of cold remedy products as reported by Information Resources Inc., ("IRI") data, general economic weakness and lower incidence of...

2009-04-30 17:53:00

SAN MATEO, Calif., April 30 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on Thursday, May 7, 2009 at 4:30 p.m. ET (1:30 p.m. PT) to report results for its first quarter 2009. The conference call will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer. To...

2009-04-30 06:00:00

DOYLESTOWN, Pa., April 30 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., www.quigleyco.com, a wholly-owned subsidiary of The Quigley Corporation (Nasdaq: QGLY) announced today that their recently completed Phase 2 double-blinded, placebo-controlled, clinical trial of diabetic peripheral neuropathy, demonstrated a significant improvement in two key measures of distal sensory nerve function in the group treated with QR333. The compound was applied topically to the feet of subjects suffering...

2009-04-29 17:32:00

Evaluation of Neurologic Safety following Treatment with Qutenza(TM) (NGX-4010) Identification of Impact of PHN and PDN on Health Care Costs SAN MATEO, Calif., April 29 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today the presentation of two posters at the 61st Annual American Academy of Neurology (AAN) meeting in Seattle, Washington. These posters, titled...

2009-03-20 07:00:00

Qutenza(TM) Receives Positive Committee Recommendation in European Union Corporate Highlights: - CHMP issued positive opinion recommending approval of Qutenza(TM) (formerly NGX-4010) for treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain - Qutenza NDA accepted for review by U.S. FDA for PHN Upcoming 2009 Milestones: - European commercial partnership for Qutenza anticipated first half of 2009 - European...

2009-03-19 15:24:00

Broad Label Indicated for Peripheral Neuropathic Pain in Non-Diabetic Adults Conference Call Scheduled Friday, March 20 at 9am ET SAN MATEO, Calif., March 19 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of...